Fosmetpantotenate

Fosmetpantotenate is a phosphopantothenic acid (PPA) precursor designed to release PPA intracellularly, leading to restoration of CoA levels. Fosmetpantotenate is used to research pantothenate kinase-associated neurodegeneration.

Product Specifications

CAS Number

[1858268-66-2]

Product Name Alternative

RE-024

UNSPSC

12352005

Target

Drug Intermediate

Type

Reference compound

Related Pathways

Others

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/fosmetpantotenate.html

Purity

98.05

Solubility

DMSO : ≥ 175 mg/mL

Smiles

COC(CCNC([C@H](O)C(C)(C)COP(OC1=CC=CC=C1)(N[C@@H](C)C(OC)=O)=O)=O)=O

Molecular Formula

C20H31N2O9P

Molecular Weight

474.44

References & Citations

[1]Elbaum D, Beconi MG, Monteagudo E, et al. Fosmetpantotenate (RE-024), a phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration: Mechanism of action and efficacy in nonclinical models. PLoS One. 2018;13 (3) :e0192028. Published 2018 Mar 9. |[2]Klopstock T, et al. The FOsmetpantotenate Replacement Therapy (FORT) randomized, double-blind, Placebo-controlled pivotal trial: Study design and development methodology of a novel primary efficacy outcome in patients with pantothenate kinase-associated neurodegeneration. Clin Trials. 2019;16 (4) :410-418.